Liquidia Corporation (LQDA) Chief Medical Officer Rajeev Saggar sold 35,365 shares of common stock for approximately $1.28 million on March 13, 2026, according to an SEC Form 4 filing. This sale is notable as it represents 16.85% of his direct holdings, significantly higher than his recent median sell transaction of 1.97%, indicating a strategic decision amid a strong performance in the stock.
The sale comes after Liquidia’s stock surged over 100% in the past year, driven by robust product sales from its recently launched drug, YUTREPIA. The company reported $148.3 million in product sales for 2025 and achieved profitability in two consecutive quarters, although it still faced a net loss of $68.9 million for the year due to increased operating expenses. Saggar retains a direct position valued at approximately $6.4 million, suggesting confidence in the company’s future prospects.
Investors should view this insider sale as a potential signal of strength rather than weakness, reflecting a strategic profit-taking move rather than a lack of confidence in Liquidia’s growth trajectory.
Source: fool.com